Grapiprant (AAT-007) is a selective EP4 prostaglandin receptor antagonist, exhibiting a Ki of 24 nM for the canine recombinant EP4 receptor. This compound is utilized in research to investigate EP4-mediated pathways in vitro and has been studied in vivo for its potential role in managing pain and inflammation associated with osteoarthritis.